---
title: "BridgeBio Oncology Therapeutics, Inc. Announces New Clinical Data for RAS and PI3Kα Programs"
description: "BridgeBio Oncology Therapeutics, Inc. announced positive preliminary safety and antitumor data for its RAS and PI3Kα programs on January 7, 2026. Key highlights include a 65% overall response rate (OR"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/271786628.md"
published_at: "2026-01-07T12:13:00.000Z"
---

# BridgeBio Oncology Therapeutics, Inc. Announces New Clinical Data for RAS and PI3Kα Programs

> BridgeBio Oncology Therapeutics, Inc. announced positive preliminary safety and antitumor data for its RAS and PI3Kα programs on January 7, 2026. Key highlights include a 65% overall response rate (ORR) for BBO-8520 in NSCLC patients with KRASG12C mutation, promising efficacy and safety when combined with pembrolizumab, and a partial response in pancreatic cancer with BBO-11818. BBO-10203 showed no hyperglycemia, leading to combination studies in CRC and BC. A company webcast is scheduled for January 7, 2026, at 8:30 a.m. ET.

**On January 7, 2026, BridgeBio Oncology Therapeutics, Inc. announced positive preliminary safety and antitumor data for its RAS and PI3Kα programs.**

**Key Highlights:**

-   BBO-8520 showed a 65% ORR in NSCLC patients with KRASG12C mutation.
-   BBO-8520 combined with pembrolizumab showed promising efficacy and safety.
-   BBO-11818 demonstrated partial response in pancreatic cancer with favorable safety.
-   BBO-10203 showed no hyperglycemia, initiating combination studies in CRC and BC.
-   Company webcast scheduled for January 7, 2026, at 8:30 a.m. ET.

Original SEC Filing: BridgeBio Oncology Therapeutics, Inc. \[ BBOT \] - 8-K - Jan. 07, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BBIO.US - Bridgebio Pharma](https://longbridge.com/en/quote/BBIO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BridgeBio Q4 revenue jumps on Attruby sales | BridgeBio's Q4 revenue surged, primarily due to a 35% increase in Attruby sales. The company reported positive Phase 3 t | [Link](https://longbridge.com/en/news/276786305.md) |
| BridgeBio Oncology Reports Positive Early Results for Three RAS and PI3Kα Cancer Therapies | BridgeBio Oncology Therapeutics Inc. (BBOT) reported positive early results from clinical studies of its three RAS and P | [Link](https://longbridge.com/en/news/271784279.md) |
| Ferguson Enterprises Inc. Provides Earnings Guidance for the Period from January 1, 2026 to December 31, 2026 | Ferguson Enterprises Inc. provided earnings guidance for the Period from January 1, 2026 to December 31, 2026. The compa | [Link](https://longbridge.com/en/news/276736124.md) |
| Pivotal Vopimetostat Pancreatic Cancer Trial Plan Might Change The Case For Investing In Tango Therapeutics (TNGX) | Tango Therapeutics, Inc. is advancing vopimetostat into a pivotal 300-patient trial for second-line pancreatic cancer, f | [Link](https://longbridge.com/en/news/276141096.md) |
| BridgeBio Oncology Touts “Best in RAS” Pipeline, Highlights BBO-8520 Response and Combo Tolerability | BridgeBio Oncology Therapeutics (NASDAQ: BBOT) executives presented their strategy for a "Best in RAS" pipeline during a | [Link](https://longbridge.com/en/news/276975538.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.